工程化自体T细胞重编程克服梅克尔细胞癌耐药
该研究针对免疫检查点抑制剂(ICI)耐药的MCPyV阳性梅克尔细胞癌(MCC),鉴定出靶向MCPyV大T抗原的HLA-A*02:01限制性高亲和力TCR(TCRMCC1),并在7例患者中开展TCR工程化T细胞治疗,观察到肿瘤浸润与2例肿瘤消退,但HLA I类沉默限制疗效;进一步工程化改造CD4/CD8 T细胞共表达CD8αβ与CD200R-CD28转换受体,在小鼠中增强肿瘤浸润、HLA表达及对HLA低表达MCC的控制。
要点
- TCRMCC1靶向MCPyV大T抗原15-23表位,为HLA-A*02:01限制性高亲和力TCR。
- 7例ICI耐药MCPyV+转移性MCC患者接受TTCR-MCC1细胞治疗,2例肿瘤消退。
- HLA I类沉默是限制疗效的常见免疫逃逸机制。
核心结论
- TCR工程化细胞治疗对MCPyV+ MCC可行,靶向增强抗原呈递可能克服免疫逃逸。
研究设计与样本
- 研究纳入7例ICI难治性转移性MCPyV+ MCC患者,接受TCRMCC1转导T细胞(TTCR-MCC1)治疗,方案包括淋巴细胞清除化疗或HLA增强干预(放疗或干扰素γ-1b),并联合ICI(NCT03747484)。
- 另开展小鼠体内实验,评估工程化CD4和CD8 TTCR-MCC1细胞共表达CD8αβ与CD200R-CD28转换受体的效果。
主要发现
- TTCR-MCC1细胞可迁移至肿瘤部位并表达T细胞活化相关基因表达谱,2例患者观察到肿瘤消退。
- 治疗活性受HLA I类沉默限制;1例患者延迟肿瘤消退伴随内源性效应免疫激活和MCC HLA表达恢复。
- 小鼠体内共表达CD8αβ与CD200R-CD28转换受体的工程化T细胞增强肿瘤浸润、增加HLA表达并改善对HLA低表达MCC的控制。
临床怎么用
- 对于ICI耐药的MCPyV+ MCC,TCR工程化T细胞治疗是可行策略,但需关注HLA I类沉默导致的耐药。
- 联合HLA增强干预(如放疗或干扰素γ-1b)可能提升TCR-T疗效,需进一步临床验证。
- 工程化共表达CD8αβ与CD200R-CD28转换受体是克服HLA沉默的潜在改造方向。
局限性
- 样本量小(7例患者),疗效证据有限。
- HLA I类沉默限制治疗活性,需额外干预克服。
- 工程化增强策略主要在 mice 中验证,尚未在患者中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICIs) have transformed Merkel cell carcinoma (MCC) outcomes, but most patients with MCC develop resistance. We identified T cell receptor (TCR)MCC1, a highly avid, HLA-A*02:01-restricted TCR targeting the Merkel cell polyomavirus (MCPyV) oncoprotein large-T antigen15-23. Seven patients with ICI-refractory metastatic MCPyV+ MCC received TCRMCC1-transduced cells (TTCR-MCC1 cells) after lymphodepleting chemotherapy or HLA-enhancing interventions [radiation or interferon gamma-1b (Actimmune)], with concurrent ICIs (NCT03747484). TTCR-MCC1 cells trafficked to tumor sites and expressed a gene expression profile compatible with T cell activation, with tumor regression observed in two patients. However, therapeutic activity was limited by HLA class I silencing, a common mechanism of immune escape in MCC. In one patient, delayed tumor regression coincided with endogenous effector immune activation and restoration of MCC HLA expression, implying that robust local responses could reverse HLA silencing. To overcome this barrier, we engineered CD4 and CD8 TTCR-MCC1 cells to coexpress CD8αβ and a CD200R-CD28 switch receptor, enabling CD4 T cell engagement and T cell costimulation. These modifications enhanced tumor infiltration, increased HLA expression, and improved control of HLAlow MCC in vivo in mice. These findings support the feasibility of TCR-engineered cell therapy for MCPyV+ MCC and provide a blueprint for overcoming immune evasion via targeted localized enhancement of antigen presentation.
引用
- Asano Y, Veatch JR, Sung CJ, et al. Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma. Sci Transl Med. 2026. PMID: 42715345. doi:10.1126/scitranslmed.aea8773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。